20 miliardi di euro l’anno: i costi per il cancro in Italia – Prevenzione attiva, la vera arma vincente
The AI that will be developed will integrate the HELIXBALANCE results with anamnestic data and the results from the other HELIXAFE tests. The purpose is to obtain validation of the AI’s ability to integrate data from HELIXBALANCE with anamnestic information and the results of the other HELIXAFE tests to profile an individual’s colorectal cancer risk. We will utilize our AI to develop a predictive algorithm and to validate new biomarkers of the cancer prodromal condition, which will allow the development of new biological or chemical agents in the field of chemoprevention. To expand the assessment in cancer driver interception, we want to replicate our work on genome instability on another physio-pathological condition that can drive cancer development: mitochondrial dysfunction. Also, we will examine the pathways known to exhibit mitochondrial dysfunction, and we will develop a tool to investigate mitochondrial dysfunction in healthy individuals.
